Related Experiment Video

Updated: Aug 15, 2026

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

Activation of dendritic cells via inhibition of Jak2/STAT3 signaling

Yulia Nefedova1, Pingyan Cheng, Daniele Gilkes

  • 1Immunology Program, H. Lee Moffitt Cancer Center, and the Department of Interdisciplinary Oncology, University of South Florida, Tampa, FL 33647, USA

Journal of Immunology (Baltimore, Md. : 1950)
|September 24, 2005
PubMed

Insights

Inhibiting the Jak2/STAT3 pathway with JSI-124 promotes dendritic cell (DC) differentiation and enhances their ability to activate T cells, offering a new strategy for cancer therapy.

Area of Science:

  • Immunology
  • Cell Biology
  • Cancer Research

Background:

  • The Janus kinase 2 (Jak2)/signal transducer and activator of transcription 3 (STAT3) pathway is crucial for normal dendritic cell (DC) differentiation.
  • Tumor-derived factors (TDF) can hyperactivate Jak2/STAT3, leading to abnormal DC differentiation in cancer.
  • Understanding this mechanism is key to developing therapeutic strategies for cancer immunotherapy.

Purpose of the Study:

  • To investigate the role of Jak2/STAT3 signaling in DC differentiation and activation.
  • To explore the potential of a novel Jak2/STAT3 inhibitor, JSI-124, for regulating DC function in cancer.

Main Methods:

  • Utilized JSI-124, a selective Jak2/STAT3 inhibitor.
  • Assessed DC differentiation and maturation markers (e.g., MHC class II, costimulatory molecules).
  • Evaluated T cell stimulatory capacity and analyzed transcription factor activation (NF-kappaB, STAT3).

Main Results:

  • JSI-124 successfully overcame TDF-induced differentiation block, promoting mature DC and macrophage differentiation.
  • Inhibition of Jak2/STAT3 led to significant activation of immature DCs, enhancing their T cell stimulatory function.
  • Jak2/STAT3 inhibition activated NF-kappaB, likely by blocking STAT3's dominant-negative effect, independent of IkappaB alpha.

Conclusions:

  • Jak2/STAT3 signaling negatively regulates DC activation.
  • Pharmacological inhibition of Jak2/STAT3 with JSI-124 can enhance DC function and T cell responses.
  • Targeting the Jak2/STAT3 pathway presents a promising strategy for improving cancer immunotherapy.

More Related Videos

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...